Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds

Jinku Kim, Aditi Sharma, Brett Runge, Heather Waters, Bruce Doll, Sean Mcbride, Pedro Alvarez, Mahrokh Dadsetan, Michael J Yaszemski, Jeffrey O. Hollinger

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.

Original languageEnglish (US)
Pages (from-to)404-413
Number of pages10
JournalJournal of Tissue Engineering and Regenerative Medicine
Volume6
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Bone Development
Osteoblasts
Scaffolds
Bone
Hydroxyapatite
Tissue engineering
Assays
Durapatite
Tissue Engineering
Bone and Bones
Proteins
Defects
Bioelectric potentials
Scaffolds (biology)
Tissue Scaffolds
Bone Morphogenetic Proteins
Alcohols
Cells
poly(caprolactone fumarate)
Osteogenesis

Keywords

  • Bone tissue engineering
  • Poly(ε-caprolactone fumarate)
  • Rabbit calvarial critical-sized defect
  • RhBMP-2
  • Three-dimensional scaffold

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Biomaterials

Cite this

Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds. / Kim, Jinku; Sharma, Aditi; Runge, Brett; Waters, Heather; Doll, Bruce; Mcbride, Sean; Alvarez, Pedro; Dadsetan, Mahrokh; Yaszemski, Michael J; Hollinger, Jeffrey O.

In: Journal of Tissue Engineering and Regenerative Medicine, Vol. 6, No. 5, 05.2012, p. 404-413.

Research output: Contribution to journalArticle

Kim, J, Sharma, A, Runge, B, Waters, H, Doll, B, Mcbride, S, Alvarez, P, Dadsetan, M, Yaszemski, MJ & Hollinger, JO 2012, 'Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds', Journal of Tissue Engineering and Regenerative Medicine, vol. 6, no. 5, pp. 404-413. https://doi.org/10.1002/term.442
Kim, Jinku ; Sharma, Aditi ; Runge, Brett ; Waters, Heather ; Doll, Bruce ; Mcbride, Sean ; Alvarez, Pedro ; Dadsetan, Mahrokh ; Yaszemski, Michael J ; Hollinger, Jeffrey O. / Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds. In: Journal of Tissue Engineering and Regenerative Medicine. 2012 ; Vol. 6, No. 5. pp. 404-413.
@article{da7ea67695954f6c8a577a742dafb0e4,
title = "Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds",
abstract = "Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.",
keywords = "Bone tissue engineering, Poly(ε-caprolactone fumarate), Rabbit calvarial critical-sized defect, RhBMP-2, Three-dimensional scaffold",
author = "Jinku Kim and Aditi Sharma and Brett Runge and Heather Waters and Bruce Doll and Sean Mcbride and Pedro Alvarez and Mahrokh Dadsetan and Yaszemski, {Michael J} and Hollinger, {Jeffrey O.}",
year = "2012",
month = "5",
doi = "10.1002/term.442",
language = "English (US)",
volume = "6",
pages = "404--413",
journal = "Journal of Tissue Engineering and Regenerative Medicine",
issn = "1932-6254",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Osteoblast growth and bone-healing response to three-dimensional poly(ε-caprolactone fumarate) scaffolds

AU - Kim, Jinku

AU - Sharma, Aditi

AU - Runge, Brett

AU - Waters, Heather

AU - Doll, Bruce

AU - Mcbride, Sean

AU - Alvarez, Pedro

AU - Dadsetan, Mahrokh

AU - Yaszemski, Michael J

AU - Hollinger, Jeffrey O.

PY - 2012/5

Y1 - 2012/5

N2 - Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.

AB - Poly(ε-caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP-2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre-osteoblast cell line (MC3T3-E1). Additionally, in vitro release profiles of rhBMP-2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP-2 release and that the released protein was bioactive. For the in vivo study, a critical-sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post-implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP-2 than in scaffolds without rhBMP-2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP-2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold.

KW - Bone tissue engineering

KW - Poly(ε-caprolactone fumarate)

KW - Rabbit calvarial critical-sized defect

KW - RhBMP-2

KW - Three-dimensional scaffold

UR - http://www.scopus.com/inward/record.url?scp=84860012874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860012874&partnerID=8YFLogxK

U2 - 10.1002/term.442

DO - 10.1002/term.442

M3 - Article

C2 - 21744511

AN - SCOPUS:84860012874

VL - 6

SP - 404

EP - 413

JO - Journal of Tissue Engineering and Regenerative Medicine

JF - Journal of Tissue Engineering and Regenerative Medicine

SN - 1932-6254

IS - 5

ER -